Infantile spasms occurring in children with tuberous sclerosis represent a specific clinical combination that calls for a targeted, condition-aware treatment approach rather than a generic spasm protocol.
A specific antiepileptic agent has shown possible effectiveness for the short-term treatment of infantile spasms in this population. The full protocol specifies the agent and its clinical use in the context of tuberous sclerosis — the complete regimen is available below.
The primary clinical targets are cessation of spasms and resolution of hypsarrhythmia within 14 days of initiation of therapy.
Vigabatrin is also possibly effective for the short-term treatment of infantile spasms in the majority of children with tuberous sclerosis (level C, class III and IV evidence).
Vigabatrin appears to be effective within 14 days of initiation of therapy.
View source ↗